In a nutshell This trial is aiming to determine how effective a new medication called elacestrant is for treating advanced breast cancer. The main outcome that will be measured is how long the patients go without the disease progressing. This study is being conducted in Illinois, United States. The details Some breast cancers grow in response to the...
Read MoreType(s) of breast cancer-Breast carcinoma Posts on Medivizor
Looking for patients with HER2 negative HR positive advanced breast cancer to test tesetaxel
In a nutshell This trial is examining the effectiveness of tesetaxel plus a reduced dose of capecitabine for hormone receptor (HR) positive/HER2 negative advanced breast cancer. The main outcome to be measured will be progression free survival (time from treatment until disease progression). The details Breast cancer is classified into...
Read MoreLooking for patients with triple negative breast cancer to test atezolizumab
In a nutshell This trial is examining the effectiveness of chemotherapy and atezolizumab (Tecentriq), given before surgery, for triple negative breast cancer. The main outcomes to be measured will be response in the breast tissue and lymph nodes and survival. The details Triple negative breast cancer is not dependent on the HER2 receptors or...
Read MoreGuidelines on dose escalation and de-escalation for early stage breast cancer
In a nutshell This item reviewed treatment guidelines that have been recommended for early stage breast cancer. Some background The St. Gallen International Breast Cancer Conference gathers leading experts in breast cancer research and makes treatment guidelines. The 2017 conference has added to the consensus on dose escalation or de-escalation...
Read MoreLooking for patients undergoing breast core biopsy to test the effectiveness of nature sounds on anxiety reduction
In a nutshell This trial is examining the effectiveness of nature sounds to reduce pain and anxiety in patients undergoing breast core biopsy. The main outcome to be measured will be anxiety and pain scores. The study is being conducted in Chicago, Illinois, in the United States. The details A biopsy can be a stressful test for patients...
Read MoreLooking for patients with metastatic triple negative breast cancer to examine the effect of Nivolumab in combination with Cabozantinib
In a nutshell This trial is examining the effectiveness of nivolumab (Opdivo) in combination with cabozantinib (Cometriq) for metastatic triple-negative breast cancer (cancer that is not dependent on hormones or HER2 for growth). The outcome to be measured will be the response rate of the cancer to this treatment. This study is...
Read MoreThe biosimilar filgrastim is effective at preventing fever during chemotherapy for breast cancer
In a nutshell This study evaluated the effectiveness of filgrastim (Neupogen) as compared to original G-CSF treatments lenograstim and pegfilgrastim (Neulasta). The study concluded that filgrastim was as effective as original G-CSF treatments. Some background Low white blood cell counts can occur...
Read MoreEndocrine therapy and targeted therapy are safe for patients over 65 with HR+/HER2- advanced breast cancer
In a nutshell This study aimed to evaluate the effectiveness and safety of endocrine therapy, with or without targeted therapy, for patients with advanced metastatic breast cancer. This study concluded that the use of endocrine therapy and targeted therapy is safe for use in patients over 65. Some background There are several treatment...
Read MoreRibociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer
In a nutshell This study aimed to determine the effectiveness and safety of ribociclib (Kisqali) combined with a non-steroidal aromatase inhibitor in elderly patients with hormone receptor positive and HER-2 negative breast cancer. This study concluded that ribociclib improved progression free survival and was relatively safe to use...
Read MoreLong-term outcomes of dose-dense chemotherapy for high-risk breast cancer
In a nutshell This study aimed to compare intense dose-dense adjuvant (after surgery) chemotherapy with conventionally scheduled chemotherapy. This study concluded that the dose-dense chemotherapy regime had a better 10-year survival and event free survival rates as compared to conventional chemotherapy. Some background Breast cancer...
Read MoreDelays in radiotherapy and recurrence in patients with ductal carcinoma in situ
In a nutshell This study aimed to investigate the association between ipsilateral breast tumor recurrence (IBTR) and the timing of radiotherapy. This study found that a delay of more than 12 weeks in starting radiotherapy was associated with a higher risk of IBTR in women undergoing BCS for ductal carcinoma in situ. Some background Breast...
Read MoreSearching for breast cancer patients with brain metastases to test a new chemotherapy drug
In a nutshell This phase 3 trial aims to compare an investigational drug to standard chemotherapy in breast cancer patients with brain metastases. The main outcome to be investigated is overall survival (time from treatment until death from any cause). Another outcome to be measured is progression free survival (time from treatment until disease...
Read More
